Amyris Inc. (AMRS) 0.52 $AMRS
Amyris Announces Collaboration with Johnson & Johnson Innovation for Biosynthetic Drug Discovery
GlobeNewswire - Mon Jun 06, 7:30AM CDT
Amyris's uPharm Platform to be Used for Rapid Integrated Discovery and Production of Therapeutic Compounds
AMRS: 0.52 (-0.02)
Gen9 and Amyris Announce Supply Agreement for Synthetic DNA
BusinessWire - Thu Jun 02, 8:00AM CDT
Gen9 and Amyris today announced an agreement for the supply of multiple megabases of synthetic DNA content. The DNA is being supplied for use in Amyris, Inc.'s (Nasdaq: AMRS) microbial engineering pipeline for the development of products that improve performance and enable sustainable growth for some of the world's leading brands. The collaboration is part of Gen9's MAP program, fueled by the BioFab(R) DNA synthesis technology, which provides valuable, high-quality synthetic DNA constructs for industrial-scale use.
AMRS: 0.52 (-0.02)
Amyris to Participate in June 2016 Investor Conferences
GlobeNewswire - Fri May 27, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it plans to participate in the following upcoming investor conferences in June 2016 and provide an update on new partnerships and growth opportunities as part of its business plan for the year.
AMRS: 0.52 (-0.02)
Amyris & CJ CheilJedang Corporation Creating Manufacturing and Sales Partnership
GlobeNewswire - Fri May 20, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, and South Korea-based CJ CheilJedang Corporation ("CJ"
(KRX:097950), today announced that the companies have signed a Memorandum of Understanding (MOU) to support large-scale manufacturing of Amyris's farnesene in existing CJ facilities. The arrangement described in the MOU would enable Amyris to utilize CJ's state of the art manufacturing capacity while minimizing the capital investment necessary to support projected near- and mid-term demand for product applications using farnesene. The partnership is also expected to include the opportunity for CJ Bio (division of CJ CheilJedang) to market select Amyris products in Asian markets as well as the potential for Amyris to develop several products for CJ Bio. The companies are targeting completing a definitive agreement by the first week of August 2016.
AMRS: 0.52 (-0.02)
Amyris to Participate in Upcoming Investor Conferences in May 2016
GlobeNewswire - Wed May 11, 1:42PM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it plans to participate in the following upcoming investor conferences in May 2016.
AMRS: 0.52 (-0.02)
Amyris reports 1Q loss
Automated Insights - Tue May 10, 6:32PM CDT
EMERYVILLE, Calif. (AP) _ Amyris Inc. (AMRS) on Tuesday reported a loss of $15.3 million in its first quarter.
AMRS: 0.52 (-0.02)
Amyris First Quarter 2016 Results Deliver Strong Renewable Product Sales Growth and Continued Reduction in Operating Expenses
GlobeNewswire - Tue May 10, 4:09PM CDT
-- Q1 2016 revenues of $8.8 million, including product sales growth of 50% over Q1 2015
AMRS: 0.52 (-0.02)
Biossance(TM) Announces the Blacklist - 2,000+ Potentially Harmful Cosmetic Ingredients it Refuses to Use while Delivering Products Consumers Love to Use
GlobeNewswire - Fri May 06, 7:30AM CDT
Biossance(TM), the pioneer of sustainable solutions in beauty from Amyris, Inc. (Nasdaq:AMRS), announced today the Blacklist - 2,000+ common cosmetic ingredients it refuses to use due to safety and environmental concerns. The regulatory environment in the U.S. affords cosmetic brands the opportunity to use potentially harmful ingredients in cosmetic products. Biossance has created higher standards by adopting rigorous ingredient selection guidelines and omitting ingredients that are potentially harmful to you or the planet.
AMRS: 0.52 (-0.02)
Amyris to Announce First Quarter Financial Results on Tuesday, May 10, 2016
GlobeNewswire - Fri Apr 29, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS) will report financial results for the first quarter ended March 31, 2016 after market close on Tuesday, May 10, 2016.
AMRS: 0.52 (-0.02)
Why Amyris Inc.'s Shares Spiked 34% Today
Travis Hoium, The Motley Fool - Motley Fool - Wed Apr 27, 12:20PM CDT
Image source: Amyris. What: Shares of Amyris Inc. jumped as much as 34% in early trading today after announcing a major supply agreement. But by midday on Wall Street, shares had settled to a more muted 7% gain. So what: Amyris said it...
AMRS: 0.52 (-0.02)
Top Stocks: Four Actively Traded Stocks on Wednesday April 27, 2016
ACCESSWIRE - Wed Apr 27, 11:35AM CDT
MIAMI, FL / ACCESSWIRE / April 27, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. MWOG, AMRS, LGCY, and ORIG have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
LGCY: 2.24 (-0.20), AMRS: 0.52 (-0.02), ORIG: 2.84 (-0.16)
Small Cap Watch: These 4 Stocks Are Making Big Moves Today
ACCESSWIRE - Wed Apr 27, 9:17AM CDT
NEW YORK, NY / ACCESSWIRE / April 27, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Tuesday. SRPT, LGCY, ORIG and AMRS are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
LGCY: 2.24 (-0.20), AMRS: 0.52 (-0.02), SRPT: 19.95 (-1.04), ORIG: 2.84 (-0.16)
Amyris Signs Five Year Biofene(R) Supply Agreement with leading Global Nutraceuticals Company with Over $100 Million of Expected Value
GlobeNewswire - Wed Apr 27, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has executed a five year Biofene supply agreement with a global nutraceuticals company. This new, long-term agreement replaces the parties' one-year purchase agreement, which was previously announced on January 4, 2016. Under the new supply agreement, the customer has agreed to a larger Biofene purchase in 2016 with an expected revenue contribution of approximately $9 million and to minimum annual purchase commitments in each of the remaining years of the agreement. In addition, under the new agreement, Amyris is entitled to a quarterly value-share arrangement on the sales of the customer's product made from the purchased Biofene. Amyris expects total revenue from the five-year agreement to be more than $100 million. In year-five of the supply agreement term, the agreement is projected to generate approximately $40 million of annual revenue, which Amyris expects will be renewed at that level in subsequent years.
AMRS: 0.52 (-0.02)
Amyris Named Gold 2016 Edison Award Winner -- One of Highest Accolades for Innovation in Business
GlobeNewswire - Mon Apr 25, 7:36AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, is pleased to announce it has been named a Gold Edison Award winner for its collaborative development work on production of artemisinin for life-saving artemisinin combination therapies (ACTs), the World Health Organization's recommended first-line treatment for malaria. The Edison Awards, named after inventor Thomas Edison, are among the most prestigious accolades a company can receive and honor new product and service development, marketing, human-centered design and innovation that are considered "game-changing."
AMRS: 0.52 (-0.02)
Amyris Creates Program to Reduce the Cost and Increase Access to Leading Malaria Treatment
GlobeNewswire - Mon Apr 11, 10:00AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced the signing of a stock purchase agreement for a $5-million equity investment from the Bill & Melinda Gates Foundation. The investment is to fund a program to further reduce the cost of one of the world's leading malaria treatments so that no child has to go without treatment for malaria. The program will focus on the continued production of high-quality and secure supplies of artemisinic acid and amorphadiene to be converted to artemisinin for use in artemisinin combination therapies ("ACTs". ACTs are recommended by the World Health Organization ("WHO" as the primary first-line treatment for malaria.
AMRS: 0.52 (-0.02)
Amyris (AMRS) Catches Eye: Stock Moves 8.7% Higher
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 7:40AM CDT
Amyris, Inc. (AMRS) saw its shares rise above 8% in the last trading session.
EVA: 23.95 (-0.25), AMRS: 0.52 (-0.02)
Amyris Brotas Plant Sold Out for 2017-2020 Farnesene Volume - Project for Dedicated Flavors & Fragrances Initiated
GlobeNewswire - Mon Mar 21, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced an expansion project to add a dedicated flavors & fragrances manufacturing unit to its Brotas industrial fermentation complex in Brazil. This planned expansion enables the company to meet demand for contracted flavors and fragrances molecules for its collaboration partners.
AMRS: 0.52 (-0.02)
Amyris Reports Fourth Quarter and Fiscal Year 2015 Financial Results
GlobeNewswire - Wed Mar 09, 3:22PM CST
-- Q4 2015 product sales marked third consecutive quarter of double-digit percentage growth,
AMRS: 0.52 (-0.02)
Amyris Announces Collaboration with Johnson & Johnson Innovation for Biosynthetic Drug Discovery
GlobeNewswire - Mon Jun 06, 7:30AM CDT
Amyris's uPharm Platform to be Used for Rapid Integrated Discovery and Production of Therapeutic Compounds
AMRS: 0.52 (-0.02)
Gen9 and Amyris Announce Supply Agreement for Synthetic DNA
BusinessWire - Thu Jun 02, 8:00AM CDT
Gen9 and Amyris today announced an agreement for the supply of multiple megabases of synthetic DNA content. The DNA is being supplied for use in Amyris, Inc.'s (Nasdaq: AMRS) microbial engineering pipeline for the development of products that improve performance and enable sustainable growth for some of the world's leading brands. The collaboration is part of Gen9's MAP program, fueled by the BioFab(R) DNA synthesis technology, which provides valuable, high-quality synthetic DNA constructs for industrial-scale use.
AMRS: 0.52 (-0.02)
Amyris to Participate in June 2016 Investor Conferences
GlobeNewswire - Fri May 27, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it plans to participate in the following upcoming investor conferences in June 2016 and provide an update on new partnerships and growth opportunities as part of its business plan for the year.
AMRS: 0.52 (-0.02)
Amyris & CJ CheilJedang Corporation Creating Manufacturing and Sales Partnership
GlobeNewswire - Fri May 20, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, and South Korea-based CJ CheilJedang Corporation ("CJ"
(KRX:097950), today announced that the companies have signed a Memorandum of Understanding (MOU) to support large-scale manufacturing of Amyris's farnesene in existing CJ facilities. The arrangement described in the MOU would enable Amyris to utilize CJ's state of the art manufacturing capacity while minimizing the capital investment necessary to support projected near- and mid-term demand for product applications using farnesene. The partnership is also expected to include the opportunity for CJ Bio (division of CJ CheilJedang) to market select Amyris products in Asian markets as well as the potential for Amyris to develop several products for CJ Bio. The companies are targeting completing a definitive agreement by the first week of August 2016. AMRS: 0.52 (-0.02)
Amyris to Participate in Upcoming Investor Conferences in May 2016
GlobeNewswire - Wed May 11, 1:42PM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it plans to participate in the following upcoming investor conferences in May 2016.
AMRS: 0.52 (-0.02)
Amyris reports 1Q loss
Automated Insights - Tue May 10, 6:32PM CDT
EMERYVILLE, Calif. (AP) _ Amyris Inc. (AMRS) on Tuesday reported a loss of $15.3 million in its first quarter.
AMRS: 0.52 (-0.02)
Amyris First Quarter 2016 Results Deliver Strong Renewable Product Sales Growth and Continued Reduction in Operating Expenses
GlobeNewswire - Tue May 10, 4:09PM CDT
-- Q1 2016 revenues of $8.8 million, including product sales growth of 50% over Q1 2015
AMRS: 0.52 (-0.02)
Biossance(TM) Announces the Blacklist - 2,000+ Potentially Harmful Cosmetic Ingredients it Refuses to Use while Delivering Products Consumers Love to Use
GlobeNewswire - Fri May 06, 7:30AM CDT
Biossance(TM), the pioneer of sustainable solutions in beauty from Amyris, Inc. (Nasdaq:AMRS), announced today the Blacklist - 2,000+ common cosmetic ingredients it refuses to use due to safety and environmental concerns. The regulatory environment in the U.S. affords cosmetic brands the opportunity to use potentially harmful ingredients in cosmetic products. Biossance has created higher standards by adopting rigorous ingredient selection guidelines and omitting ingredients that are potentially harmful to you or the planet.
AMRS: 0.52 (-0.02)
Amyris to Announce First Quarter Financial Results on Tuesday, May 10, 2016
GlobeNewswire - Fri Apr 29, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS) will report financial results for the first quarter ended March 31, 2016 after market close on Tuesday, May 10, 2016.
AMRS: 0.52 (-0.02)
Why Amyris Inc.'s Shares Spiked 34% Today
Travis Hoium, The Motley Fool - Motley Fool - Wed Apr 27, 12:20PM CDT
Image source: Amyris. What: Shares of Amyris Inc. jumped as much as 34% in early trading today after announcing a major supply agreement. But by midday on Wall Street, shares had settled to a more muted 7% gain. So what: Amyris said it...
AMRS: 0.52 (-0.02)
Top Stocks: Four Actively Traded Stocks on Wednesday April 27, 2016
ACCESSWIRE - Wed Apr 27, 11:35AM CDT
MIAMI, FL / ACCESSWIRE / April 27, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. MWOG, AMRS, LGCY, and ORIG have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
LGCY: 2.24 (-0.20), AMRS: 0.52 (-0.02), ORIG: 2.84 (-0.16)
Small Cap Watch: These 4 Stocks Are Making Big Moves Today
ACCESSWIRE - Wed Apr 27, 9:17AM CDT
NEW YORK, NY / ACCESSWIRE / April 27, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Tuesday. SRPT, LGCY, ORIG and AMRS are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
LGCY: 2.24 (-0.20), AMRS: 0.52 (-0.02), SRPT: 19.95 (-1.04), ORIG: 2.84 (-0.16)
Amyris Signs Five Year Biofene(R) Supply Agreement with leading Global Nutraceuticals Company with Over $100 Million of Expected Value
GlobeNewswire - Wed Apr 27, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it has executed a five year Biofene supply agreement with a global nutraceuticals company. This new, long-term agreement replaces the parties' one-year purchase agreement, which was previously announced on January 4, 2016. Under the new supply agreement, the customer has agreed to a larger Biofene purchase in 2016 with an expected revenue contribution of approximately $9 million and to minimum annual purchase commitments in each of the remaining years of the agreement. In addition, under the new agreement, Amyris is entitled to a quarterly value-share arrangement on the sales of the customer's product made from the purchased Biofene. Amyris expects total revenue from the five-year agreement to be more than $100 million. In year-five of the supply agreement term, the agreement is projected to generate approximately $40 million of annual revenue, which Amyris expects will be renewed at that level in subsequent years.
AMRS: 0.52 (-0.02)
Amyris Named Gold 2016 Edison Award Winner -- One of Highest Accolades for Innovation in Business
GlobeNewswire - Mon Apr 25, 7:36AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, is pleased to announce it has been named a Gold Edison Award winner for its collaborative development work on production of artemisinin for life-saving artemisinin combination therapies (ACTs), the World Health Organization's recommended first-line treatment for malaria. The Edison Awards, named after inventor Thomas Edison, are among the most prestigious accolades a company can receive and honor new product and service development, marketing, human-centered design and innovation that are considered "game-changing."
AMRS: 0.52 (-0.02)
Amyris Creates Program to Reduce the Cost and Increase Access to Leading Malaria Treatment
GlobeNewswire - Mon Apr 11, 10:00AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced the signing of a stock purchase agreement for a $5-million equity investment from the Bill & Melinda Gates Foundation. The investment is to fund a program to further reduce the cost of one of the world's leading malaria treatments so that no child has to go without treatment for malaria. The program will focus on the continued production of high-quality and secure supplies of artemisinic acid and amorphadiene to be converted to artemisinin for use in artemisinin combination therapies ("ACTs"
. ACTs are recommended by the World Health Organization ("WHO" as the primary first-line treatment for malaria. AMRS: 0.52 (-0.02)
Amyris (AMRS) Catches Eye: Stock Moves 8.7% Higher
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 7:40AM CDT
Amyris, Inc. (AMRS) saw its shares rise above 8% in the last trading session.
EVA: 23.95 (-0.25), AMRS: 0.52 (-0.02)
Amyris Brotas Plant Sold Out for 2017-2020 Farnesene Volume - Project for Dedicated Flavors & Fragrances Initiated
GlobeNewswire - Mon Mar 21, 7:30AM CDT
Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced an expansion project to add a dedicated flavors & fragrances manufacturing unit to its Brotas industrial fermentation complex in Brazil. This planned expansion enables the company to meet demand for contracted flavors and fragrances molecules for its collaboration partners.
AMRS: 0.52 (-0.02)
Amyris Reports Fourth Quarter and Fiscal Year 2015 Financial Results
GlobeNewswire - Wed Mar 09, 3:22PM CST
-- Q4 2015 product sales marked third consecutive quarter of double-digit percentage growth,
AMRS: 0.52 (-0.02)
